Quantcast

Latest Human Genome Sciences Stories

2009-07-19 23:05:00

ROCKVILLE, Maryland July 20 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) will host a conference call today at 8:15 AM Eastern to discuss the results from BLISS-52, the first of two pivotal Phase 3 clinical trials of BENLYSTA(TM) (belimumab, formerly LymphoStat-B(R)) in systemic lupus erythematosus (SLE). (Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO ) Investors may listen to the call by dialing 888-632-5010 or 913-312-0402, passcode 8364417, five...

2009-07-19 23:01:00

ROCKVILLE, Maryland and LONDON, July 20 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) and GlaxoSmithKline PLC (GSK) today announced that BENLYSTA(TM) (belimumab, formerly LymphoStat-B(R)) met the primary endpoint in BLISS-52, the first of two pivotal Phase 3 trials in patients with serologically active systemic lupus erythematosus (SLE). In the placebo-controlled BLISS-52 study, the results showed that belimumab plus standard of care achieved a clinically and...

2009-07-09 06:00:00

ROCKVILLE, Md., July 9 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced publication by The New England Journal of Medicine of the results of two pivotal animal efficacy studies, which showed the life-saving potential of the Company's human monoclonal antibody drug raxibacumab (ABthrax(TM)), as well as the results of human safety studies, which supported the use of raxibacumab in the event of life-threatening inhalation anthrax disease. (Logo:...

2009-07-01 06:00:00

ROCKVILLE, Maryland, July 1 /PRNewswire-USNewswire/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it expects to have top-line results available on Monday, July 20, from BLISS-52, the first of two pivotal Phase 3 clinical trials of BENLYSTA(TM) (belimumab, formerly LymphoStat-B(R)) in systemic lupus erythematosus (SLE). (Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO ) Senior management will host a conference call to discuss the results on Monday, July 20,...

2009-06-19 07:00:00

ROCKVILLE, Md., June 19 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) announced today that its presentation at the 2009 Piper Jaffray Europe Conference will be webcast and may be accessed at www.hgsi.com. (Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO ) A member of Human Genome Sciences' senior management team will present a corporate overview on Tuesday, June 23, 2009 at 10:30 am GMT (6:30 am Eastern Time). Investors interested in listening to the live...

2009-06-19 06:00:00

- Trial conducted by Novartis evaluating safety and efficacy of Albuferon administered every four weeks in combination with ribavirin in patients with genotypes 2 and 3 hepatitis C - ROCKVILLE, Md., June 19 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that Novartis has completed enrollment and initial dosing in a Phase 2b clinical trial to evaluate the safety and efficacy of Albuferon(R) (albinterferon alfa-2b) administered monthly in combination with...

2009-06-11 06:00:00

- Phase 2 continuation data demonstrated sustained improvement in disease activity and patient response rate through four years of BENLYSTA therapy - - Frequency of disease flares as measured by the SELENA SLEDAI flare index and by BILAG A or B organ domain scores decreased over four years of BENLYSTA therapy - - No increase in overall adverse events, serious adverse events, malignancies or serious infections over time - ROCKVILLE, Md., June 11 /PRNewswire-FirstCall/ -- Human Genome...

2009-06-08 11:50:00

ROCKVILLE, Md., June 8 /PRNewswire-FirstCall/ -- Attached is a press release issued yesterday by GlaxoSmithKline (GSK), regarding new Phase 2 data for Syncria(R) (albiglutide) presented at the American Diabetes Association 69th Scientific Sessions in New Orleans.   (Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO )   Syncria is a biological product generated from the genetic fusion of human albumin and modified human GLP-1 peptide, and is designed to act throughout the...

2009-05-21 06:00:00

- First-in-class treatment for inhalation anthrax - ROCKVILLE, Md., May 21 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its human monoclonal antibody drug ABthrax(TM) (raxibacumab) for the treatment of inhalation anthrax. (Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO ) The BLA submission includes the results of two...

2009-05-07 06:01:00

ROCKVILLE, Md. and NOTTINGHAM, UK, May 7 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) and Novozymes Biopharma, a part of Novozymes (Nasdaq: NZYM B), today announced that they have amended an existing license agreement to allow both companies to expand application of their proprietary albumin fusion technology. (Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO) Under the amended agreement, HGS and Novozymes each has the opportunity to exclusively license...


Word of the Day
monteith
  • A large punch-bowl of the eighteenth century, usually of silver and with a movable rim, and decorated with flutings and a scalloped edge. It was also used for cooling and carrying wine-glasses.
  • A kind of cotton handkerchief having white spots on a colored ground, the spots being produced by a chemical which discharges the color.
This word is possibly named after Monteith (Monteigh), 'an eccentric 17th-century Scotsman who wore a cloak scalloped at the hem.'
Related